Tempus AI (NASDAQ:TEM) Sets New 12-Month Low – Should You Sell?

Tempus AI, Inc. (NASDAQ:TEM)’s share price reached a new 52-week low on Tuesday . The company traded as low as $41.46 and last traded at $41.4930, with a volume of 613604 shares. The stock had previously closed at $42.91.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating on shares of Tempus AI in a research report on Friday, July 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Tempus AI in a research report on Wednesday, June 17th. Jefferies Financial Group began coverage on Tempus AI in a research note on Monday, April 13th. They issued an “underperform” rating and a $35.00 price objective for the company. Guggenheim lifted their target price on Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Finally, Wall Street Zen raised Tempus AI from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Nine investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Tempus AI has a consensus rating of “Hold” and an average price target of $68.92.

Tempus AI Trading Down 3.1%

The company’s 50 day simple moving average is $51.49 and its 200-day simple moving average is $52.92. The firm has a market cap of $7.46 billion, a P/E ratio of -24.16 and a beta of 3.46. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last released its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. During the same quarter in the prior year, the firm posted ($0.24) earnings per share. The company’s quarterly revenue was up 36.1% on a year-over-year basis. As a group, research analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO James William Rogers sold 11,529 shares of the business’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $55.00, for a total transaction of $634,095.00. Following the completion of the sale, the chief financial officer directly owned 114,866 shares of the company’s stock, valued at approximately $6,317,630. The trade was a 9.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 8,703 shares of the company’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the completion of the transaction, the executive vice president owned 128,215 shares in the company, valued at approximately $5,650,435.05. The trade was a 6.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 449,793 shares of company stock worth $23,248,231 over the last ninety days. Corporate insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Large investors have recently added to or reduced their stakes in the stock. JPL Wealth Management LLC purchased a new position in shares of Tempus AI during the third quarter worth approximately $26,000. Los Angeles Capital Management LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd purchased a new stake in shares of Tempus AI in the third quarter valued at approximately $38,000. Whittier Trust Co. grew its stake in Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after purchasing an additional 570 shares in the last quarter. Finally, Lodestone Wealth Management LLC bought a new position in Tempus AI in the fourth quarter worth approximately $42,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.